

**Notice of References Cited**Application/Control No.  
09/693,754Applicant(s)/Patent Under  
Reexamination  
BERINSTEIN ET AL.Examiner  
Anne M BeckerlegArt Unit  
1632

Page 1 of 1

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Salgaller et.al.; Immunization against Epitopes in the Human Melanoma Antigen gp100 following Patent Immunization with Synthetic Peptides, 1996, Cancer Research 56: 4749-4757.
	V	Zaremba et.al.; Identification of an Enhancer Agonist Cytotoxic T Lymphocyte Peptide from Human Carcinoembryonic Antigen, 1997, Cancer Research 57: 4570-4577.
	W	Hurpin et.al.; The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity, 1998, Vaccine, Vol. 16, No. 2/3: 208-215.
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.